Clinical Scorecard: Advancing Precision Medicine for Pediatric Brain and Spinal Cord Tumors
At a Glance
Category
Detail
Condition
Pediatric brain and spinal cord tumors, a biologically heterogeneous group of central nervous system tumors
Key Mechanisms
Tumor development can involve molecular changes that disrupt normal cellular processes; distinct molecular drivers, cellular origins, and clinical trajectories contribute to tumor heterogeneity.
Target Population
Children with suspected or diagnosed brain or spinal cord tumors
Care Setting
Multidisciplinary pediatric neuro-oncology care, including diagnostic evaluation, molecular tumor board review, treatment planning, and research.
Key Highlights
Contemporary classification integrates histopathology with molecular and genomic characterization.
Diagnostic workup may include next-generation sequencing, DNA methylation profiling, and germline genetic testing when clinically appropriate.
Molecular findings can refine diagnosis and prognosis, inform treatment decisions, and identify potential targeted therapy or clinical trial options.
Children with suspected or confirmed brain or spinal cord tumors; the article provides no medication-specific prescribing data.
Treatment is individualized using tumor biology and clinical information. Options described include surgery, radiation therapy, multimodal treatment, targeted therapies, and clinical trials; selection depends on the tumor and patient.
Clinical Best Practices
Coordinate evaluation through a multidisciplinary pediatric neuro-oncology team, involving relevant specialists as needed.
Interpret molecular results in the context of clinical history, imaging, pathology, and patient-specific characteristics.
Use molecular characterization alongside histopathology to support diagnosis and treatment decisions.
The source describes molecular findings as potentially identifying targeted therapy opportunities and clinical trial eligibility.
